PATIENTS WITH BRCA MUTATIONS HAVE SUPERIOR OUTCOMES AFTER INTRAPERITONEAL CHEMOTHERAPY (IP) IN OPTIMALLY RESECTED HIGH GRADE OVARIAN CANCER (HGOC)

被引：0
|
作者：
Naumann, R. W. [1 ]
Symanowski, J. T. [2 ]
Morris, J. [1 ]
Crane, E. [1 ]
Tait, D. [1 ]
Higgins, R. V. [1 ]
Drury, L. [1 ]
North, L. [1 ]
Brown, J. [1 ]
机构：
[1] Carolinas Med Ctr, Levine Canc Inst, Ob Gyn, Charlotte, NC 28203 USA
[2] Carolinas Med Ctr, Levine Canc Inst, Biostat, Charlotte, NC 28203 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-1393
引用
收藏
页码：789 / 790
页数：2
相关论文
共 50 条
  • [21] CYTOLOGICAL SAMPLES FOR DETECTION OF BRCA 1/2 MUTATIONS IN PATIENTS WITH HIGH GRADE SEROUS OVARIAN CANCER
    Skof, E.
    Novakovic, S.
    Stegel, V.
    Miceska, S.
    Krajc, M.
    Bebar, S.
    Kloboves-Prevodnik, V.
    Dragos, V. Setrajcic
    Blatnik, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A196 - A197
  • [22] Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study
    Oaknin, A.
    Roda, D.
    Gonzalez-Martin, A.
    Garcia-Donas, J.
    de Juan, A.
    Redondo, A.
    Catot, S.
    del Campo, J. M.
    Perez, X.
    Poveda, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 463 - 463
  • [23] Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: A gynecologic oncology group study
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    Darcy, Kathleen M.
    Armstrong, Deborah K.
    Kulasingam, Shalini
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4144 - 4150
  • [24] DETECTION OF BRCA 1/2 MUTATIONS FROM CYTOLOGICAL SAMPLES IN PATIENTS WITH HIGH GRADE SEROUS OVARIAN CANCER
    Skof, E.
    Gornjec, A.
    Novakovic, S.
    Stegel, V.
    Krajc, M.
    Strojnik, K.
    Blatnik, A.
    Bebar, S.
    Djurisic, A.
    Merlo, S.
    Pohar-Marinsek, Z.
    Kloboves-Prevodnik, V.
    Gazic, B.
    Hocevar, M.
    Skerl, P.
    Klancar, G.
    Dragos, V. Setrajcic
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 840 - 840
  • [25] Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
    Ji, Gang
    Yao, Qianlan
    Bao, Longlong
    Zhang, Jing
    Bai, Qianming
    Zhu, Xiaoli
    Tu, Xiaoyu
    Bi, Rui
    Zhou, Xiaoyan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (06)
  • [26] Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer
    Zhang, Guonan
    Zhang, Jie
    Zhu, Yi
    Liu, Hong
    Shi, Yu
    Mi, Kun
    Li, Meiying
    Zhao, Qi
    Huang, Ziyi
    Huang, Jianming
    EXPERIMENTAL CELL RESEARCH, 2021, 406 (01)
  • [27] Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy
    Lee, Young Joo
    Shin, Yoon Kyung
    Kim, Nae Ry
    Kim, Se Ik
    Lee, Yoo-Young
    Park, Jeong-Yeol
    Kim, Jae-Weon
    Cho, Hyun-Woong
    Lee, Jung-Yun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [28] Germline vs. somatic BRCA mutations and response to chemotherapy and outcomes in serous ovarian cancer
    Chan, J. K.
    Kiet, T. K.
    Chen, L.
    Ruskin, R.
    Sherman, A. E.
    Monk, B. J.
    Kapp, D. S.
    Krivak, T. C.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 436 - 436
  • [29] Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer
    Sohn, Insuk
    Jung, Woon Yong
    Sung, Chang Ohk
    GYNECOLOGIC ONCOLOGY, 2012, 126 (01) : 103 - 108
  • [30] CLINICAL OUTCOMES OF POST-OPERATIVE INTRAPERITONEAL CHEMOTHERAPY FOR PATIENTS WITH EARLY STAGE HIGH GRADE SEROUS OVARIAN CANCER TREATED AT BRITISH COLUMBIA CANCER AGENCY
    Lee, S.
    Albert, A.
    Kumar, A.
    Kwon, J.
    Tinker, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A487 - A487
12345